Yahoo

Discover 3 ASX Penny Stocks With Market Caps Over A$100M

As Australian shares continue a five-day loss streak, diverging from Wall Street's record highs, investors are keenly observing the market dynamics. Penny stocks, though often seen as speculative, still hold potential when backed by robust financials and strategic positioning. In this article, we explore three promising penny stocks on the ASX that demonstrate notable financial strength and could offer intriguing opportunities for those seeking to invest in smaller or newer companies.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

LaserBond (ASX:LBL)

A$0.5475

A$64.92M

★★★★★★

Regal Partners (ASX:RPL)

A$2.37

A$871.55M

★★★★★★

Praemium (ASX:PPS)

A$0.69

A$336.36M

★★★★★★

Ora Banda Mining (ASX:OBM)

A$1.54

A$2.97B

★★★★★★

Australian Ethical Investment (ASX:AEF)

A$4.21

A$479.22M

★★★★★★

EDU Holdings (ASX:EDU)

A$0.905

A$112.35M

★★★★★★

Integrated Research (ASX:IRI)

A$0.30

A$54.18M

★★★★★★

CTI Logistics (ASX:CLX)

A$1.75

A$141.57M

★★★★☆☆

Cogstate (ASX:CGS)

A$2.44

A$416.84M

★★★★★★

GWA Group (ASX:GWA)

A$2.02

A$524.67M

★★★★★☆

Click here to see the full list of 387 stocks from our ASX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

EDU Holdings

Simply Wall St Financial Health Rating:★★★★★★

Overview:EDU Holdings Limited, with a market cap of A$112.35 million, operates through its subsidiaries to offer tertiary education services in Australia.

Operations:The company generates revenue through its subsidiaries, with Ikon Institute of Australia contributing A$65.95 million and Australian Learning Group Pty Limited adding A$16.46 million to its educational services portfolio in Australia.

Market Cap:A$112.35M

EDU Holdings, with a market cap of A$112.35 million, has demonstrated significant financial growth and stability. Its return on equity is outstanding at 65.8%, indicating strong profitability, while its short-term assets exceed both short and long-term liabilities, highlighting financial health. The company has experienced remarkable earnings growth of 469.3% over the past year, far surpassing industry averages. EDU is debt-free and trading at a good value compared to peers. Recent developments include a completed share buyback program worth A$9.9 million and an annual dividend announcement of A$0.03 per share, reflecting shareholder value enhancement efforts despite recent board changes.

ASX:EDU Revenue & Expenses Breakdown as at Apr 2026
ASX:EDU Revenue & Expenses Breakdown as at Apr 2026

United Overseas Australia

Simply Wall St Financial Health Rating:★★★★★★

Overview:United Overseas Australia Ltd operates in property investment and development across Malaysia, Singapore, Vietnam, and Australia, with a market cap of A$1.28 billion.

Operations:The company does not report specific revenue segments.

Market Cap:A$1.28B

United Overseas Australia Ltd, with a market cap of A$1.28 billion, has shown robust earnings growth of 60.4% over the past year, surpassing its five-year average and outperforming the real estate industry. The company maintains strong financial health with short-term assets of A$1.5 billion covering both short and long-term liabilities comfortably. Recent executive changes include appointing Kong Sze Hou as Director to enhance Vietnam operations, reflecting strategic regional focus. Despite an unstable dividend track record, a recent dividend declaration underscores efforts to return value to shareholders amidst stable weekly volatility and improved profit margins from last year's figures.

ASX:UOS Financial Position Analysis as at Apr 2026
ASX:UOS Financial Position Analysis as at Apr 2026

Vitrafy Life Sciences

Simply Wall St Financial Health Rating:★★★★★★

Overview:Vitrafy Life Sciences Limited focuses on the research, development, and commercialization of cryopreservation solutions in Australia with a market cap of A$127.06 million.

Operations:The company generates revenue of A$2.34 million from its Research and Development segment.

Market Cap:A$127.06M

Vitrafy Life Sciences Limited, with a market cap of A$127.06 million, is pre-revenue, generating minimal sales of A$0.0089 million as of the last half-year report. Despite being debt-free and having short-term assets exceeding liabilities, the company remains unprofitable with a negative return on equity and increasing losses over five years. The management team and board are relatively new, indicating potential strategic shifts but lacking seasoned leadership experience. Revenue is forecast to grow significantly at 102.1% per year; however, profitability isn't expected in the near term. Vitrafy has a cash runway sufficient for over a year under current conditions.

ASX:VFY Debt to Equity History and Analysis as at Apr 2026
ASX:VFY Debt to Equity History and Analysis as at Apr 2026

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:EDU ASX:UOS and ASX:VFY.

This article was originally published by Simply Wall St .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Mobilize your Website
View Site in Mobile | Classic
Share by: